India To Study Black Holes With First Satellite Launch After U.S.
(Bloomberg) -- India launched its first satellite on Monday to study black holes as it seeks to deepen its space exploration efforts ahead of an ambitious crewed mission next year.
The spacecraft, named X-ray Polarimeter Satellite, was propelled into an orbit of 350 kilometers from an island near India's main spaceport of Sriharikota, off the southern state of Andhra Pradesh, according to S. Somanath, chairman of the Indian Space Research Organisation.
The satellite, weighing about 470 kilograms, will carry out research on X-rays emanating from around 50 celestial objects with the help of two payloads built by ISRO and a Bengaluru-based research institute.
NASA launched a similar mission, the Imaging X-ray Polarimetry Explorer, in 2021 to answer questions such as why black holes spin and build on the findings of its flagship telescope Chandra X-ray Observatory that blasted off more than two decades ago. China's National Space Administration launched the country's first X-ray space telescope to observe black holes, pulsars and gamma-ray bursts in 2017.
India's upcoming projects include its first launch of astronauts on a crewed mission, named Gaganyaan, scheduled for 2025. After a successful spacecraft landing near the lunar south pole last year, India is planning to develop a next-generation launch vehicle and a new launchpad, with the goal of landing people on the moon by 2040.
The country is also seeking to tie up with other space majors to further its ambitions. NASA Administrator Bill Nelson visited India in November ahead of a joint US-Indian Earth-observing mission scheduled for launch in 2024.
More stories like this are available on bloomberg.com
©2024 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.